Brodalumab

Drug Profile

Brodalumab

Alternative Names: AMG-827; IL-17R mAb; KHK-4827; LUMICEF; Siliq

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Kyowa Hakko Kirin; Valeant Pharmaceuticals International
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Spondylarthritis
  • Discontinued Asthma; Crohn's disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 16 Feb 2017 Label for Brodalumab in USA carries black box warning regarding risks in patients with history of suicidal thoughts or behaviour
  • 15 Feb 2017 Registered for Plaque psoriasis in USA (SC)
  • 15 Feb 2017 Pooled adverse events data from its phase III trials in Plaque psoriasis released by US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top